New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:28 EDTCYCCCyclacel outlines the company's key clinical development objectives
Cyclacel Pharmaceuticals provided an outline of the company's key clinical development objectives for 2014. For Sapacitabine in SEAMLESS, the company plans to continue enrollment and expand study into Europe to at least double enrolling sites, report next interim periodic DSMB review at approximately 300 patients enrolled, report DSMB interim analysis for futility after 212 events, and complete enrollment. For Sapacitabine in MDS, the company plans to announce registration-directed, clinical development plan in 2nd line MDS following treatment failure after hypomethylating agents. For Sapacitabine in solid tumors, the company plans to report updated Phase 1 sapacitabine and seliciclib combination data in patients with solid tumors including those carrying the gBRCA mutation. The company also plans to advance early pipeline.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
09:15 EDTCYCCOn The Fly: Pre-market Movers
HIGHER: Anavex Life Sciences (AVXL), up 20.5% after 3-71 data published in Neurodegenerative Diseases... Oramed Pharmaceuticals (ORMP), up 16.7% after signing up to $50M licensing and investment agreements for insulin in China... Horizon Pharma (HZNP), up 3.8% after receiving EC approval for Ravicti... Fitbit (FIT), up 4.2% after being upgraded to Overweight from Equal Weight at Barclays... Sarepta Therapeutics (SRPT), up 1.6% following a positive mention by Barron's. LOWER: Cyclacel Pharmaceuticals (CYCC) and AEterna Zentaris (AEZS), down 24.5% and 13.6%, respectively, following a Tweet by KaloBios (KBIO) CEO Martin Shkreli... Supercom (SPBC), down 21.6% after reporting preliminary third quarter revenue... Macrocure (MCUR), down 11.5% after announcing that the company's CFO and Chief Medical Officer are stepping down... lululemon (LULU), down 4.4% after being downgraded to Underperform from Market Perform at FBR Capital... Office Depot (ODP), down 2.8% after the NY Post reported that regulators are preparing to block Staples' (SPLS) proposed acquisition of Office Depot... SouFun (SFUN), down 2% after being downgraded to Neutral from Buy at Goldman.
08:59 EDTCYCCCyclacel Pharmaceuticals, Aeterna Zentaris 'worthless,' says Shkreli
Martin Shkreli, the CEO KaloBios (KBIO) and Turing Pharma, said in a tweet that Cyclacel Pharmaceuticals (CYCC) and Aeterna Zentaris (AEZS) shares are "worthless." Shares of both stocks are indicated lower this morning following Shkreli's Twitter post. Reference Link
November 23, 2015
07:17 EDTCYCCCyclacel Pharmaceuticals says CDK2/9 inhibitor prolings survival
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use